In conclusion, the present study indicates that the hepatoprotective drug matrine may offer protective effects against NASH via suppression of hepatic inflammation, fibrosis and damage, possibly via the upregulation of HSP72 and the downregulation of mTOR (Figure 7). The gene discussed is MTOR; the disease is metabolic dysfunction-associated steatohepatitis.